Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters











Publication year range
1.
Genes Immun ; 15(6): 370-7, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24898387

ABSTRACT

We analyzed two West African samples (Guinea-Bissau: n=289 cases and 322 controls; The Gambia: n=240 cases and 248 controls) to evaluate single-nucleotide polymorphisms (SNPs) in Epiregulin (EREG) and V-ATPase (T-cell immune regulator 1 (TCIRG1)) using single and multilocus analyses to determine whether previously described associations with pulmonary tuberculosis (PTB) in Vietnamese and Italians would replicate in African populations. We did not detect any significant single locus or haplotype associations in either sample. We also performed exploratory pairwise interaction analyses using Visualization of Statistical Epistasis Networks (ViSEN), a novel method to detect only interactions among multiple variables, to elucidate possible interaction effects between SNPs and demographic factors. Although we found no strong evidence of marginal effects, there were several significant pairwise interactions that were identified in either the Guinea-Bissau or the Gambian samples, two of which replicated across populations. Our results indicate that the effects of EREG and TCIRG1 variants on PTB susceptibility, to the extent that they exist, are dependent on gene-gene interactions in West African populations as detected with ViSEN. In addition, epistatic effects are likely to be influenced by inter- and intra-population differences in genetic or environmental context and/or the mycobacterial lineages causing disease.


Subject(s)
Epiregulin/genetics , Genetic Predisposition to Disease/genetics , Polymorphism, Single Nucleotide , Tuberculosis, Pulmonary/genetics , Vacuolar Proton-Translocating ATPases/genetics , Adult , Alleles , Black People/genetics , Epistasis, Genetic , Gambia , Gene Frequency , Genetic Predisposition to Disease/ethnology , Genotype , Guinea-Bissau , Humans , Linkage Disequilibrium , Logistic Models , Male , Odds Ratio , Tuberculosis, Pulmonary/ethnology
2.
Oncogene ; 28(46): 4075-94, 2009 Nov 19.
Article in English | MEDLINE | ID: mdl-19734938

ABSTRACT

Hsp90 chaperones stabilize many tyrosine kinases including several oncogenes, which are inhibited or induced to degrade by the Hsp90 inhibitor geldanamycin (GA). As a consequence, GA has been developed for future chemotherapeutic use in several tumour types including neuroblastoma (NB). Alternative splicing of the neurotrophin receptor tyrosine kinase TrkA may have a pivotal function in regulating NB behaviour, with reports suggesting that tumour-suppressing signals from TrkA may be converted to oncogenic signals by stress-regulated alternative TrkAIII splicing. Within this context, it is important to know whether Hsp90 interacts with TrkA variants in NB cells and how GA influences this. Here, we report that both TrkAI and TrkAIII are Hsp90 clients in human NB cells. TrkAI exhibits GA-sensitive interaction with Hsp90 required for receptor endoplasmic reticulum export, maturation, cell surface stabilization and ligand-mediated activation, whereas TrkAIII exhibits GA-sensitive interactions with Hsp90 required for spontaneous activity and to a lesser extent stability. We show that GA inhibits proliferation and induces apoptosis of TrkAI expressing NB cells, whereas TrkAIII reduces the sensitivity of NB cells to GA-induced elimination. Our data suggest that GA-sensitive interactions with Hsp90 are critical for both TrkAI tumour suppressor and TrkAIII oncogenic function in NB and that TrkAIII expression exerts a negative impact on GA-induced NB cell eradication, which can be counteracted by a novel TrkAIII-specific peptide nucleic acid inhibitor.


Subject(s)
Benzoquinones/pharmacology , HSP90 Heat-Shock Proteins/metabolism , Lactams, Macrocyclic/pharmacology , Neuroblastoma/metabolism , Receptor, trkA/metabolism , Alternative Splicing , Antigens, Surface/metabolism , Enzyme Stability/drug effects , Genes, Tumor Suppressor/drug effects , Genes, Tumor Suppressor/physiology , Humans , Isoenzymes/metabolism , Isoenzymes/physiology , Neuroblastoma/genetics , Neuroblastoma/pathology , Oncogenes/drug effects , Oncogenes/physiology , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Kinase Inhibitors/pharmacology , Protein Transport/drug effects , Receptor, trkA/antagonists & inhibitors , Receptor, trkA/genetics , Receptor, trkA/physiology , Transfection , Tumor Cells, Cultured , Tyrosine/metabolism
3.
Neurology ; 65(10): 1631-5, 2005 Nov 22.
Article in English | MEDLINE | ID: mdl-16301493

ABSTRACT

BACKGROUND: Spinal muscular atrophy (SMA) is a recessive neurodegenerative disorder characterized by the loss of alpha-motor neurons in the spinal cord and subsequent death of motor neuron cells. SMA occurs with a frequency of 1 in 6,000 live births, with a carrier frequency of 1 in 40, and is a leading genetic cause of infant mortality. SMA is caused by loss or mutation of the telomeric survival motor neuron gene (SMN1), which is deleted in almost 94% of SMA patients OBJECTIVE: To analyze the transmission ratio at the SMA locus, examining the segregation of the SMN1-deleted alleles in 314 fetuses from carrier parents who requested prenatal testing for the disease. METHODS: Prenatal diagnosis of SMA in families at 25% risk of the disease has been performed on chorionic villous sampling specimens, through direct detection of the SMN1 gene mutation and linkage analysis using microsatellite markers from the 5q13 region. Analysis of the genotypic/allelic frequencies of the SMN1 gene was performed using the chi2 test, assuming a recessive mendelian inheritance. RESULTS: Of 314 fetuses analyzed, 95 were homozygous for the wild-type allele (30.3%), 154 were carriers (49.0%), and the remaining 65 were homozygous for the mutated allele (20.7%). Statistical analysis demonstrated that proportion of fetuses predicted with SMA is lower than 25% expected for a recessive disorder, resulting in a transmission rate of the SMN1-deleted allele deviant from the 50% expected in a random the segregation of a mendelian tract (p = 0.016) CONCLUSIONS: This is the first study to evaluate the genotypic frequencies at the spinal muscular atrophy (SMA) locus based on data derived from prenatal analysis, which are not subject to ascertainment bias. The analysis showed a transmission ratio distortion at the SMA locus in favor of the SMN1 wild-type alleles.


Subject(s)
Cyclic AMP Response Element-Binding Protein/genetics , Gene Deletion , Genetic Predisposition to Disease/genetics , Inheritance Patterns/genetics , Muscular Atrophy, Spinal/diagnosis , Muscular Atrophy, Spinal/genetics , Nerve Tissue Proteins/genetics , RNA-Binding Proteins/genetics , Chorionic Villi Sampling , Chromosome Mapping , Chromosomes, Human, Pair 5/genetics , DNA Mutational Analysis , Female , Gene Frequency , Genes, Recessive/genetics , Genetic Counseling , Genetic Testing , Genotype , Heterozygote , Homozygote , Humans , Microsatellite Repeats/genetics , Mutation/genetics , Pregnancy , Prenatal Diagnosis , SMN Complex Proteins , Survival of Motor Neuron 1 Protein
4.
Genet Test ; 5(1): 33-7, 2001.
Article in English | MEDLINE | ID: mdl-11336398

ABSTRACT

Spinal muscular atrophy (SMA) is an autosomal recessive disorder with a newborn prevalence of 1 in 10,000, and a carrier frequency of 1 in 40-60 individuals. The SMA locus has been mapped to chromosome 5q11.2-13. The disease is caused by a deletion of the SMN gene, often encompassing other genes and microsatellite markers. The SMN gene is present in two highly homologous copies, SMN1 and SMN2, differing at five nucleotide positions. Only homozygous SMN1 mutations cause the disease. The sequence similarity between the SMN1 and SMN2 genes can make molecular diagnosis and carrier identification difficult. We developed a sensitive and reliable molecular test for SMN1 carrier identification, by setting up a nonradioactive single strand conformation polymorphism (SSCP)-based method, which allows for the quantification of the amount of the SMN1 gene product with respect to a control gene. The assay was validated in 56 obligate (ascertained) carriers and 20 (ascertained) noncarriers. The sensitivity of the test is 96.4%, and its specificity, 98%. In addition, 6 of 7 SMA patients without homozygous deletions presented with a heterozygous deletion, suggesting a concomitant undetected point mutation on the nondeleted SMN1 allele. Therefore, the present test is effective for detecting compound hemizygote patients, for testing carriers in SMA families, and for screening for SMA heterozygotes in the general population.


Subject(s)
Genetic Testing/methods , Heterozygote , Muscular Atrophy, Spinal/genetics , Mutation/genetics , Nerve Tissue Proteins/genetics , Polymorphism, Single-Stranded Conformational , Alleles , Cyclic AMP Response Element-Binding Protein , Humans , Muscular Atrophy, Spinal/diagnosis , Point Mutation , RNA-Binding Proteins , SMN Complex Proteins , Sensitivity and Specificity , Sequence Deletion , Survival of Motor Neuron 1 Protein , Survival of Motor Neuron 2 Protein
5.
Eur J Biochem ; 268(2): 405-13, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11168376

ABSTRACT

Thioredoxin (Trx) inhibited tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 activity with an approximate IC50 of 0.3 microM, matrix metalloproteinase (MMP)-2 activity with an approximate IC50 of 2 microM but did not inhibit MMP-9 activity. This differential capacity of Trx to inhibit TIMP and MMP activity resulted in the promotion of MMP-2 and MMP-9 activity in the presence of molar TIMP excess. Inhibition of TIMP and MMP-2 activity by Trx was dependent upon thioredoxin reductase (TrxR), was abolished by Trx catalytic site mutation and did not result from TIMP or MMP-2 degradation. HepG2 hepatocellular carcinoma cells induced to secrete Trx inhibited TIMP activity in the presence of TrxR. SK-N-SH neuroblastoma cells secreted TrxR, which inhibited TIMP and MMP-2 activity in the presence of Trx. Trx stimulated SK-N-SH invasive capacity in vitro in the absence of exogenous TrxR. This study therefore identifies a novel extracellular role for the thioredoxin/thioredoxin reductase redox system in the differential inhibition of TIMP and MMP activity and provides a novel mechanism for altering the TIMP/MMP balance that is of potential relevance to tumor invasion.


Subject(s)
Matrix Metalloproteinase Inhibitors , Neoplasm Invasiveness , Neuroblastoma/pathology , Thioredoxins/pharmacology , Tissue Inhibitor of Metalloproteinases/antagonists & inhibitors , Disulfides/metabolism , Humans , Matrix Metalloproteinase 9/metabolism , Neoplasm Proteins/metabolism , Neoplasm Proteins/pharmacology , Thioredoxin-Disulfide Reductase/metabolism , Thioredoxins/metabolism , Tissue Inhibitor of Metalloproteinase-1/antagonists & inhibitors , Tissue Inhibitor of Metalloproteinase-2/antagonists & inhibitors , Tumor Cells, Cultured
6.
Am J Hum Genet ; 67(4): 1004-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10986044

ABSTRACT

Multinodular goiter (MNG) is a common disorder characterized by a nodular enlargement of the thyroid gland and occurring with a female&rcolon;male ratio of 5&rcolon;1. This article reports the analysis of an Italian three-generation pedigree MNG, including 10 affected females and 2 affected males. After linkage to candidate regions previously implicated in various forms of goiter was excluded, a novel MNG locus was searched. Because no male-to-male transmission was present in the study pedigree, an X-linked autosomal dominant pattern of inheritance was hypothesized. Therefore, 18 markers spaced at 10-cM intervals on the X chromosome were examined. A significant LOD score was observed in the Xp22 region, where marker DXS1226 generated a maximum LOD score of 4.73 at a recombination fraction of 0. Analysis of six flanking microsatellites confirmed these data, and haplotype inspection delimited a 9.6-cM interval lying between DXS1052 and DXS8039.


Subject(s)
Genes, Dominant/genetics , Genetic Linkage/genetics , Goiter, Nodular/genetics , X Chromosome/genetics , Chromosome Mapping , Female , Haplotypes/genetics , Humans , Italy , Lod Score , Male , Microsatellite Repeats/genetics , Pedigree
7.
Cell Growth Differ ; 10(5): 353-67, 1999 May.
Article in English | MEDLINE | ID: mdl-10359016

ABSTRACT

Spontaneous epithelial (S) to neuroblast (N) conversion enhanced the capacity of SK-N-SH neuroblastoma (NB) cells to invade reconstituted basement membrane in vitro. This involved a switch to matrix metalloproteinase (MMP) activity, in particular MMP-9, and was associated with the induction of MMP-9 expression. N-type-specific MMP-9 expression was herbimycin A inhibitable tyrosine kinase (possibly c-src) dependent and was regulated transcriptionally through GT-box (-52), and nuclear factor kappaB (NFkappaB; -600) elements within the MMP-9 gene. GT-box function was associated with elevated levels of specific nuclear GT-box binding complexes in N-type cells. NFkappaB function was associated with specific p50- and p65-containing nuclear NFkappaB binding complex(es). No function could be attributed to the proximal AP-1 (-79) element, and minimal function was attributed to the SP-1 (-560), ets (-540), or distal AP-1 (-533) elements. This was despite elevated levels of specific junD/fra-1 containing proximal AP-1 element binding complex(es) in N-type cells. Our data highlight a pivotal role for the GT-box, in concert with the NFkappaB element, in the transcriptional up-regulation of MMP-9 expression during spontaneous S to N phenotype conversion by SK-N-SH cells involved in enhanced basement membrane invasivity.


Subject(s)
Collagenases/genetics , NF-kappa B/metabolism , Neoplasm Invasiveness , Neuroblastoma/pathology , Neurons/cytology , Transcription, Genetic , Up-Regulation , Benzoquinones , Binding Sites , CSK Tyrosine-Protein Kinase , Cell Extracts , Cell Nucleus/metabolism , Collagenases/physiology , Enzyme Inhibitors/pharmacology , Epithelial Cells , Humans , Lactams, Macrocyclic , Matrix Metalloproteinase 9 , Phenotype , Promoter Regions, Genetic , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/metabolism , Quinones/pharmacology , Response Elements , Rifabutin/analogs & derivatives , Sp1 Transcription Factor/metabolism , Transcription Factor AP-1/metabolism , Transcriptional Activation , Tumor Cells, Cultured , src-Family Kinases
8.
Cancer Res ; 58(14): 2957-60, 1998 Jul 15.
Article in English | MEDLINE | ID: mdl-9679953

ABSTRACT

The degradation of tissue inhibitor of metalloproteinase (TIMP)-free matrix metalloproteinase (MMP)-2 to proteolytically inactive fragments by plasmin was inhibited in equimolar mixtures of purified TIMP-2 and TIMP-free MMP-2 and was not observed in purified MMP-2-TIMP-2 complexes. Divalent cation chelators EDTA and sodium Alendronate did not inhibit plasmin degradation of TIMP-free MMP-2 but reversed the ability of TIMP-2 to protect MMP-2 from degradation by plasmin. Our data confirm a role for plasmin in the clearance of TIMP-free MMP-2, identify a pivotal role for TIMP-2 in regulating MMP-2 longevity in plasmin-containing environments, and highlight a novel therapeutic use for chelators of divalent cations, including the bisphosphonate Alendronate, in the reversal of TIMP-2 protection of MMP-2 from degradation by plasmin. We propose that these observations are relevant to pathologies that are dependent upon plasmin and MMP-2 activity (e.g., tumor invasion and metastasis).


Subject(s)
Fibrinolysin/antagonists & inhibitors , Gelatinases/drug effects , Metalloendopeptidases/drug effects , Protease Inhibitors/pharmacology , Tissue Inhibitor of Metalloproteinase-2/pharmacology , Alendronate/pharmacology , Cations , Chelating Agents/pharmacology , Diphosphonates/pharmacology , Edetic Acid/pharmacology , Fibrinolysin/metabolism , Gelatinases/metabolism , Humans , Matrix Metalloproteinase 2 , Metalloendopeptidases/metabolism , Tumor Cells, Cultured/drug effects
9.
Int J Cancer ; 77(1): 82-93, 1998 Jul 03.
Article in English | MEDLINE | ID: mdl-9639398

ABSTRACT

We show that osteopontin (OPN), bone sialoprotein (BSP) and GRGDSP peptides, in solution, induce activation of metalloproteinase-2 (MMP-2) secreted by human GCT23 giant cell tumour cells. Activation of MMP-2 is RGD sequence dependent, possibly involves anti-alphaVbeta3 integrins, is preceded by a change from spread to rounded cell morphology and is mimicked by the actin depolymerising agent cytochalasin B. Cells that had spread on OPN, BSP and GRGDSP substrata failed to activate MMP-2, but subsequent addition of soluble GRGDSP induced rounding and MMP-2 activation. Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity. Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2. GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2. This was consistent with the possible relocation of constitutive MT-MMP-1 to the cell surface as a prerequisite for subsequent cell surface MMP-2/TIMP-2/MT-MMP-1 complex formation and to the potential induction of conditions favourable for reciprocal cell surface MMP-1/MMP-2 activation. Our data provide a novel insight into interactions between RGD containing bone matrices, GCT cells and MMPs of potential relevance to GCT pathology.


Subject(s)
Carcinoma, Giant Cell/enzymology , Gelatinases/metabolism , Metalloendopeptidases/metabolism , Oligopeptides/genetics , Oligopeptides/pharmacology , Sialoglycoproteins/pharmacology , Carcinoma, Giant Cell/genetics , Carcinoma, Giant Cell/pathology , Cell Size/drug effects , Cell Size/genetics , Enzyme Activation/drug effects , Enzyme Activation/genetics , Gene Expression Regulation, Neoplastic/drug effects , Humans , Integrin-Binding Sialoprotein , Matrix Metalloproteinase 2 , Osteopontin , Tumor Cells, Cultured
10.
Int J Cancer ; 75(5): 721-30, 1998 Mar 02.
Article in English | MEDLINE | ID: mdl-9495240

ABSTRACT

Transforming growth factor-beta (TGFbeta1) enhances human MDA-MB-231 breast tumour cell invasion of reconstituted basement membrane in vitro but does not inhibit proliferation of this cell line. In contrast to basal invasion, which is plasmin-, urokinase (uPA)-, tissue-type plasminogen activator (t-PA)-, matrix metalloproteinase (MMP)-9- and TIMP-1-inhibitable MMP-dependent, TGFbeta1 enhanced-invasion is dependent upon plasmin and uPA activity but does not appear to involve t-PA-, MMP9- or TIMP-1-inhibitable MMPs, as judged by inhibitor studies. Enhanced invasion is associated with increased u-PA, UPAR, PAI-1, MT-MMP-1, MMP-9 and TIMP-1 expression; with reduced t-PA, MMP-1 and MMP-3 expression; and with the induction of membrane MMP-9 association. The net result of these changes includes increased secreted, but not membrane-associated, uPA levels and activity and reduced secreted levels of plasmin and APMA-activatable gelatinolytic, collagenolytic and caseinolytic MMP activity but no change in membrane-associated gelatinolytic activity, despite increased MT-MMP-1 expression and MMP-9 membrane association. TGFbeta1 does not induce MMP-2 expression. Our data indicate that TGFbeta1 can promote the malignant behaviour of MDA-MB-231 cells refractory to TGFbeta1-mediated proliferation control by enhancing their invasive capacity. We suggest that this results from the action of a uPA/plasmin-dependent mechanism resulting from stimulation of uPA expression, secretion and subsequent activity, despite elevated PAI-1 inhibitor levels.


Subject(s)
Breast Neoplasms/pathology , Neoplasm Invasiveness , Transforming Growth Factor beta/pharmacology , Urokinase-Type Plasminogen Activator/metabolism , Breast Neoplasms/enzymology , Caseins/metabolism , Collagen/metabolism , Drug Combinations , Humans , Laminin , Matrix Metalloproteinase 3/metabolism , Plasminogen Activator Inhibitor 1/metabolism , Proteoglycans , Receptors, Transforming Growth Factor beta/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Up-Regulation
11.
Int J Cancer ; 73(5): 740-8, 1997 Nov 27.
Article in English | MEDLINE | ID: mdl-9398056

ABSTRACT

Al-trans retinoic acid (RA) enhanced human, S-type, SK-N-SH neuroblastoma cell invasion of reconstituted basement membrane in vitro but did not induce terminal differentiation of this cell line. In contrast to basal invasion, which was urokinase (uPA)- and plasmin-dependent, RA-enhanced invasion was dependent on tissue-type plasminogen activator (t-PA) and plasmin activity. Neither basal nor RA-enhanced invasion involved TIMP-2 inhibitable metalloproteinases. Enhanced invasion was associated with the induction of t-PA expression, increased expression of the putative t-PA receptor amphoterin, increased association of t-PA with cell membranes and increased net membrane-associated PA activity. Enhanced invasion was not associated with significant changes in the expression of uPA or its membrane receptor UPAR; plasminogen activator inhibitors PAI-1 and PAI-2; metalloproteinases MMP-1, MMP-2, MMP-3, MMP-9 and membrane type MMP1; or tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2. RA stimulated the association of t-PA with the external cell membrane surface, which could be inhibited by heparin sulphate but not by mannose sugars or chelators of divalent cations, consistent with a role for amphoterin. Our data indicate that RA can promote the malignant behavior of S-type neuroblastoma cells refractory to RA-mediated terminal differentiation by enhancing their basement membrane invasive capacity. We suggest that this results from the action of a novel, RA-regulated mechanism involving stimulation of t-PA expression and its association with the cell membrane leading to increased PA-dependent matrix degradation.


Subject(s)
Antineoplastic Agents/pharmacology , Neuroblastoma/pathology , Tissue Plasminogen Activator/metabolism , Tretinoin/pharmacology , Basement Membrane/drug effects , Basement Membrane/metabolism , Basement Membrane/pathology , Biocompatible Materials , Brain-Derived Neurotrophic Factor/metabolism , Cell Division/drug effects , Collagen , Drug Combinations , Humans , Laminin , Metalloendopeptidases/metabolism , Neoplasm Invasiveness , Neuroblastoma/metabolism , Phenotype , Plasminogen Activator Inhibitor 1/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Proteoglycans , Receptor Protein-Tyrosine Kinases/metabolism , Receptor, trkB , Receptors, Nerve Growth Factor/metabolism , Tissue Inhibitor of Metalloproteinases/metabolism , Tumor Cells, Cultured
12.
Cell Growth Differ ; 8(7): 789-800, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9218873

ABSTRACT

In this study, the regulatory elements involved in ICAM-1 transcriptional response to phorbol ester (12-0-tetradecanoylphorbol-13-acetate; TPA) have been investigated in the human neuroblastoma cell line, SK-N-SH. TPA induced intercellular adhesion molecule 1 (ICAM-1) protein expression in SK-N-SH cells within 24 h of treatment as judged by indirect immunofluorescence. Basal ICAM-1 mRNA levels were barely detectable in untreated SK-N-SH cells but were induced by TPA to a maximal level with 4 h and were reduced thereafter. Analysis of the 5' promoter sequence of ICAM-1 revealed two regions that functioned equally in the TPA induction of ICAM-1 transcription. The first region (-145 to -227) contained a nuclear factor-kappa B (NF kappa B) element. The second region (-316 to -390) contained a putative TPA-responsive element (TRE; TGATTCA) and a TATA box. Deletion and point mutation of the latter region indicated that the TRE was indeed the functional element within this region and acted fully and independently of all other elements including the TATA box at position -352. This TRE bound TPA induced specific nuclear complexes in vitro containing junD, c-jun, c-fos, and fra2 but not cAMP-responsive element binding/activating transcription factor family proteins. ICAM-TRE binding activity was induced within 30 min following TPA treatment. This preceded the appearance of ICAM-NF kappa B site binding activity. Cotransfection of c-jun and c-fos expression vectors into SK-N-SH cells induced transactivation from ICAM-1 promoter constructs containing the intact but not mutated TRE site. Primer extension analyses revealed that TPA had induced transcription exclusively at two sites -40 and -41 bp upstream of the translation start site. These data show that the ICAM-TRE and its cognate jun- and fos-containing transcription factors play a predominant role in the transcriptional response of ICAM-1 to the protein kinase C activator TPA in SK-N-SH cells.


Subject(s)
Intercellular Adhesion Molecule-1/genetics , Neuroblastoma/genetics , Regulatory Sequences, Nucleic Acid/genetics , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factor AP-1/metabolism , Transcriptional Activation/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , DNA, Neoplasm/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/genetics , Humans , NF-kappa B/metabolism , Protein Binding , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/biosynthesis , Proto-Oncogene Proteins c-jun/metabolism , RNA, Messenger/analysis , TATA Box/genetics , Transcription, Genetic/genetics , Transcriptional Activation/drug effects
13.
Biotechniques ; 21(5): 904-9, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8922633

ABSTRACT

Matrigel, a basement membrane (BM) extract of the Engelbreth-Holm-Swarm (EHS) sarcoma, used in tumor invasion assays, was found to contain plasminogen. Plasminogen was identified, using Western blot analysis and casein zymograms, by comparison with human plasminogen. matrigel contained approximately 20-100 ng of plasminogen per 100 micrograms of protein as determined by these assays. Matrigel reconstitution and incubation at 37 degrees C caused activation of plasminogen, which was serine protease dependent and involved tissue plasminogen activator (tPA) as an anti-tPA antibody which inhibited activation. This reconstitution and incubation also caused leupeptin-inhibitable degradation of Matrigel components as assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Degradation of the BM extract copolymerized in zymograms was caused by human plasminogen and plasminogen in the Matrigel. Maximal plasmin activity, following incubation of Matrigel at 37 degrees C for 16 h, was equivalent to approximately 10 ng of purified plasmin using the plasmin substrate D-Val-Leu-Lys p-nitroanilide. matrigel, therefore, contained all the components of the plasmin-generating system, including plasminogen. The plasmin generated degraded Matrigel components and exogenous substrates. Our data suggest that, since this tumor BM acts as a reservoir for enzymes of the plasmin-generating system, caution should be taken by investigators interpreting data concerning the effects of Matrigel on cell behavior and, in particular, cellular invasion.


Subject(s)
Collagen/analysis , Laminin/analysis , Plasminogen/analysis , Proteoglycans/analysis , Basement Membrane/chemistry , Drug Combinations , Fibrinolysin/metabolism , Humans
14.
Int J Cancer ; 69(5): 386-93, 1996 Oct 21.
Article in English | MEDLINE | ID: mdl-8900372

ABSTRACT

We have examined the expression of 2 tumor-associated metalloproteinases, MMP-2 and MMP-9, in 48 primary cultures of prostatic carcinoma (PRCA) and 33 cultures of benign prostatic hyperplasia (BPH). PRCA cultures secrete significantly more MMP-9 than their benign counterparts. Secreted MMP-2 did not differ significantly in cultures but was lower in PRCA cultures. Two cultures of benign origin exhibited high MMP-9 secretion and growth patterns consistent with a malignancy. Both cases were followed and successively re-evaluated histologically and rediagnosed as organ-confined PRCA. MMP expression in culture may be of predictive value in the identification of incidental PRCA. MMP-9 secretion and its ratio with MMP-2 were highest in epithelial cultures from invasive, metastatic tumors when compared both to disease confined to prostate gland and to locally extensive disease. MMP-9 secretion was greatest also in cultures derived from tissues of high Gleason histological grade. Active MMP-9 species were detected in 15 cultures (31%) of PRCA. Active MMP-2 species were observed in cultures of both BPH and PRCA origin in almost the same amounts. Although average levels were not significantly different, as a ratio to proform species, a significant elevation was observed in cultures of PRCA origin. We propose, therefore, that an elevated expression of MMP-9 and a high ratio of MMP-9 to MMP-2 in short-term prostate epithelial cultures is of potential diagnostic and prognostic significance.


Subject(s)
Metalloendopeptidases/metabolism , Prostatic Neoplasms/diagnosis , Diagnosis, Differential , Dose-Response Relationship, Drug , Epidermal Growth Factor/pharmacology , Epithelium/metabolism , Humans , Male , Metalloendopeptidases/analysis , Metalloendopeptidases/drug effects , Neoplasm Staging , Prostatic Neoplasms/classification , Prostatic Neoplasms/enzymology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL